[{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts","type":"changed","fields":[{"field":"tldr","before":"\"The new weight-loss injections lower weight by 15-20%. Early observational data suggest fewer obesity-related cancers in people who take them, but no trial has yet tested cancer as an outcome.\"","after":"\"GLP-1 agonists, the new weight-loss injections, lower weight by 15-20%. Early observational data suggest fewer obesity-related cancers in people who take them, but no trial has yet tested cancer as an outcome.\""}]},{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/","commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"sections"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"principle"},{"field":"strengths"},{"field":"limitations"},{"field":"cancers"},{"field":"technologies"},{"field":"terms"},{"field":"companies"},{"field":"bottlenecks"},{"field":"related"},{"field":"links"}]}]